Below, I delve into the prescription drug forecasts and show you some pretty charts. Highlights:

Prescription drug spending growth, which was negative in 2012, is projected to accelerate to 5.2% in 2014.

From 2012 to 2022, annual expenditures will grow by $194.2 billion (+75%), to $455.0 billion. During this period, Outpatient prescription drugs will be at about 9% of total U.S. healthcare spending.

Health care reform will add an extra $15.3 billion in annual drug spending by 2022. This is far below last year’s projected incremental $25.9 billion in spending by 2021.

In a future article, I’ll look at who will be paying for all of these drugs. In the meantime, pity the poor government economists tasked with forecasting healthcare spending. They must bravely peer beyond today’s pitched political battles and economic uncertainty—and then hurl a guess at the 2022 dartboard. Chin up, chaps!THE DATA

CMS’ economic boffins publish annual projections for U.S. National Health Expenditures (NHE), including prescription drugs sold through outpatient retail, mail, and specialty pharmacies.

Expenditure (spending) data differ from that of pharmacy revenues, manufacturer sales, and provider purchases. NHE totals are net of manufacturer rebates, so the reported figures are lower than pharmacies’ prescription revenues. The data also do not measure *total* U.S. spending on prescription drugs, because these data exclude an indeterminate amount of inpatient spending on pharmaceuticals. Thus, U.S. drug spending is roughly equivalent to total outpatient pharmacy revenues minus manufacturer rebates.

FWIW, the projections incorporate the Supreme Court decisions regarding the Affordable Care Act and the one-year delay in the employer mandate. CMS also did their best with the Medicaid expansion, which is still uncertain in many states. (Click here for a good Kaiser white paper on state Medicaid expansion decisions.)

The chart below presents the most recent forecasts for annual growth in total national healthcare expenditures and outpatient prescription drugs, including the impact of the Patient Protection and Affordable Care Act (PPACA). The forecasts presume timely implementation of the law. Um, yeah, right…

As you can see, CMS estimates that outpatient prescription drug spending declined by -0.8% in 2012, and projects growth will be only 0.6% in 2013. Here are the key components of the forecast period:

Prescription drug spending growth is projected to accelerate to 5.2% in 2014. This growth will result from the PPACA’s expanding access to insurance coverage in 2014 and, as the economy improves, greater prescription utilization by people with insurance. (For more on the macroeconomy angle, see my 2013 data crush in A Very Cool Look at Healthcare Spending and the Economy.)

After 2014, CMS forecasts that drug spending will be comparable with the overall growth in national health expenditures. From 2012 through 2022, outpatient prescription drugs will remain at about 9% of total U.S. healthcare spending.

CMS projects outpatient prescription drug spending will grow at a compound average rate of 6.5% from 2014 to 2022. During this period, there will be fewer generic launches and new, more expensive specialty drugs. CMS projects that the generic dispensing rate will plateau at 85%, which is slightly below other forecasts.

The aging of the U.S. population will also boost prescription utilization.

THE IMPACT OF HEALTHCARE REFORM

From 2012 to 2022, annual expenditures will grow by $194.2 billion (+75%), to $455.0 billion. Retail drug spending is projected to be $15.3 billion (+3.5%) higher in 2022 than it would have been without the PPACA.

“In the first year of the projection period, the prescription drug growth projection ranged from 6.1 percentage points below to 3.3 percentage points above the actual spending growth estimate. For the second year of the projection period, the projection range was larger, from 6.3 percentage points below to 5.4 percentage points above the actual spending growth estimate. And for the third year of the projection period, the projection range was even larger, from 10.2 percentage points below to 6.4 percentage points above.”

DISCLAIMERThe analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., Drug Channels Institute, and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

The comments contained on this site come from members of the public and do not necessarily reflect the views of Drug Channels Institute or the author. Neither Drug Channels Institute nor the author endorse or approve of their content. Drug Channels Institute and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions.

The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site. The material on this site is protected by copyright law. Unauthorized reproduction or distribution of this material may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. We do not intend to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws. We do not permit our articles to be republished without prior written permission.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels Institute, or any of its employees.